Alt Text
Office of Neuroscience Research > WUSTL Neuroscience News > New collaboration with Pfizer aimed at speeding drug discovery

New collaboration with Pfizer aimed at speeding drug discovery



From the WUSTL Newsroom...

Washington University in St. Louis is collaborating with the biopharmaceutical company Pfizer Inc. on research aimed at speeding the development of new drugs. The university is the first academic institution in the Midwest to join Pfizer’s Centers for Therapeutic Innovation’s (CTI) collaborative network.

The new collaboration is aimed at supporting translational research that has the greatest potential to bring innovative therapies to patients. The collaboration will focus on certain rare diseases, as well as on immunology and inflammation, oncology, neuroscience, and cardiovascular and metabolic diseases. In particular, the program will focus on approaches that involve large-molecule therapeutics and antibodies that have the potential to address multiple diseases.

“We are excited to be combining the resources and expertise of Pfizer scientists with the talents of our Washington University faculty in this effort to develop the next generation of therapeutics,” said Jennifer K. Lodge, vice chancellor for research at Washington University and a professor of molecular microbiology at the School of Medicine. “With our strength in basic science and translational research and the expertise of Pfizer in drug development, the new collaboration could help St. Louis and our region become even better positioned to make major contributions to benefit patients.”

CTI brings together academic and National Institutes of Health (NIH) researchers with Pfizer scientists and patient foundations, to collaborate in drug discovery in broad areas of interest to the global pharmaceutical maker.

For the complete article, click here.